Key Updates in the Treatment of HER2-Positive Breast Cancer

Gain expert insights on current and emerging HER2-targeted therapies for patients with HER2-positive metastatic breast cancer, including best practice for managing treatment-related adverse events.
person default
Jeremy M. Force, DO, MA
Nicholas P. McAndrew, MD, MSCE
Sara Tolaney, MD, MPH

Downloadable Slideset

Download this slideset from Jeremy Force, DO, MA; Nicholas McAndrew, MD, MSCE, and Sara M. Tolaney, MD, MPH with the most recent data for managing patients with HER2-positive advanced breast cancer.

person default Jeremy M. Force, DO, MA Nicholas P. McAndrew, MD, MSCE Sara Tolaney, MD, MPH Released: May 11, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

In partnership with
Supported by an educational grant from
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue